262 related articles for article (PubMed ID: 16773184)
21. [Tumor infiltrating dendritic cells and Mucin1 gene expression in benign prostatic hyperplasia and prostate cancer].
Xiang ST; Zhou SW; Guan W; Wang QZ; Zhang B; Liu JH; Ye ZQ
Zhonghua Nan Ke Xue; 2003 Oct; 9(7):497-500. PubMed ID: 14628595
[TBL] [Abstract][Full Text] [Related]
22. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H; Denardo GL; Denardo SJ
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.
Magro G; Schiappacassi M; Perissinotto D; Corsaro A; Borghese C; Belfiore A; Colombatti A; Grasso S; Botti C; Bombardieri E; Perris R
J Pathol; 2003 Jul; 200(3):357-69. PubMed ID: 12845632
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody CC188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny.
Xu M; Yuan Y; Xia Y; Achilefu S
Clin Cancer Res; 2008 Nov; 14(22):7461-9. PubMed ID: 19010863
[TBL] [Abstract][Full Text] [Related]
25. Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity.
Mazor Y; Keydar I; Benhar I
Mol Immunol; 2005 Jan; 42(1):55-69. PubMed ID: 15488944
[TBL] [Abstract][Full Text] [Related]
26. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
[TBL] [Abstract][Full Text] [Related]
27. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).
Karsten U; Serttas N; Paulsen H; Danielczyk A; Goletz S
Glycobiology; 2004 Aug; 14(8):681-92. PubMed ID: 15115750
[TBL] [Abstract][Full Text] [Related]
28. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
29. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.
Peat N; Gendler SJ; Lalani N; Duhig T; Taylor-Papadimitriou J
Cancer Res; 1992 Apr; 52(7):1954-60. PubMed ID: 1372533
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical staining of mucin 1 in prostate tissues.
Rabiau N; Dechelotte P; Guy L; Satih S; Bosviel R; Fontana L; Kemeny JL; Boiteux JP; Bignon YJ; Bernard-Gallon D
In Vivo; 2009; 23(2):203-7. PubMed ID: 19414404
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
32. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy.
Cloosen S; Arnold J; Thio M; Bos GM; Kyewski B; Germeraad WT
Cancer Res; 2007 Apr; 67(8):3919-26. PubMed ID: 17440107
[TBL] [Abstract][Full Text] [Related]
33. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
[TBL] [Abstract][Full Text] [Related]
34. Mucin glycoproteins as tumor markers.
Feller WF; Henslee JG; Kinders RJ; Manderino GL; Tomita JT; Rittenhouse HG
Immunol Ser; 1990; 53():631-72. PubMed ID: 2100576
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer associated mucin: a review.
Segal-Eiras A; Croce MV
Allergol Immunopathol (Madr); 1997; 25(4):176-81. PubMed ID: 9269507
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.
Liu H; Moy P; Kim S; Xia Y; Rajasekaran A; Navarro V; Knudsen B; Bander NH
Cancer Res; 1997 Sep; 57(17):3629-34. PubMed ID: 9288760
[TBL] [Abstract][Full Text] [Related]
38. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis.
Xu Y; Zhang L; Hu G
Biologicals; 2009 Jan; 37(1):18-25. PubMed ID: 18848467
[TBL] [Abstract][Full Text] [Related]
39. Antigens for the selection of pan-variable number of tandem repeats motif-specific human antibodies against Mucin-1.
Persson J; Ohlin M
J Immunol Methods; 2006 Oct; 316(1-2):116-24. PubMed ID: 17022996
[TBL] [Abstract][Full Text] [Related]
40. Expression of Vicia villosa agglutinin (VVA)-binding glycoprotein in primary breast cancer cells in relation to lymphatic metastasis: is atypical MUC1 bearing Tn antigen a receptor of VVA?
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T; Kanno M; Igarashi S
Breast Cancer Res Treat; 2006 Jul; 98(1):31-43. PubMed ID: 16752227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
